Pediatric related risk factors in acute and delayed chemotherapyinduced nausea and vomiting: multivariate analysis

ABSTRACT

Objectives: This study aimed to characterize the clinical profile and the factors that predispose chemotherapy-induced nausea and vomiting (CINV) in the acute and delayed phases.

Methods: A retrospective cohort study was conducted in a Brazilian hospital with pediatric patients under 18 years old receiving moderately or highly emetogenic chemotherapy. Thus, a descriptive analysis was performed to characterize this population, followed by univariate and multivariate analysis to evaluate the risk factors for CINV. In both phases, considering significant the variables with p-values <0.05.

Results: The median age was 6 and 71% of the patients included used highly emetogenic protocols. Furthermore, 41% and 76% did not have vomit in the acute and delayed phase, respectively. Through logistic regression, it is noted that patients with bone tumors and sarcomas have higher CINV in the acute phase (OR 10.0, 95%IC 1.1-88.9, p=0.039), while patients who do not have complete control in the acute phase are more likely to have CINV in the delayed phase (OR 11.8, 95%IC 1.1-130.5, p=0.044).

Conclusion: These results suggest that bone tumors and sarcomas are associated with an increase in CINV in the acute phase. In addition, control in the acute phase is associated with a complete response in the delayed phase.

RESUMO

Objetivos: Este estudo teve como objetivo caracterizar o perfil clínico e os fatores que predispõem a náuseas e vômitos induzidos por quimioterapia (NVIQ) nas fases aguda e tardia.

Métodos: Foi realizado um estudo de coorte retrospectivo em um hospital brasileiro com pacientes pediátricos menores de 18 anos recebendo quimioterapia moderada ou altamente emetogênica. Assim, foi realizada uma análise descritiva para caracterizar essa população, seguida de análise univariada e multivariada para avaliar os fatores de risco para NVIQ. Em ambas as fases, considerando significativas as variáveis com valores de p<0,05.

Resultados: A mediana de idade foi de 6 anos e 71% dos pacientes incluídos usavam protocolos altamente emetogênicos. Além disso, 41% e 76% não apresentaram vômito na fase aguda e tardia, respectivamente. Por meio de regressão logística, nota-se que pacientes com tumores ósseos e sarcomas apresentam maior NVIQ na fase aguda (OR 10,0, IC95% 1,1-88,9, p=0,039), enquanto os pacientes que não possuem controle completo na fase aguda são maior probabilidade de ter CINV na fase tardia (OR 11,8, IC95% 1,1-130,5, p=0,044).

Conclusão: Esses resultados sugerem que tumores ósseos e sarcomas estão associados a um aumento de NVIQ na fase aguda. Além disso, o controle na fase aguda está associado a uma resposta completa na fase tardia.

Keywords:

Vomiting - Chemotherapy - Pediatric - Oncology - Antiemetics

Descritores:

Vômitos - Quimioterapia - Pediátrico - Oncologia - Antieméticos

Publikationsverlauf

Eingereicht: 11. August 2021

Angenommen: 23. Oktober 2021

Artikel online veröffentlicht:
09. März 2022

• REFERENCES

• 1 Rao KV, Faso A. Chemotherapy-induced nausea and vomiting: optimizing prevention and management. Am Health Drug Benefits 2012; Jul; 5 (04) 232-240
• 2 Navari RM. Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. Biomed Res Int 2015; 2015: 595894
• 3 Di Mattei VE, Carnelli L, Carrara L, Bernardi M, Crespi G, Rancoita PMV. et al. Chemotherapy-induced nausea and vomiting in women with gynecological cancer: a preliminary single-center study investigating medical and psychosocial risk factors. Cancer Nurs 2016; Nov/Dec; 39 (06) e52-e9
• 4 Du Bois A, Meerpohl HG, Vach W, Kommoss FG, Fenzl E, Pfleiderer A. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer 1992; 28 (2-3): 450-457
• 5 Navari RM. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochim Biophys Acta 2015; Oct; 1848 (10 Pt B): 2738-2746
• 6 Roscoe JA, Morrow GR, Colagiuri B, Heckler CE, Pudlo BD, Colman L. et al. Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer 2010; 18 (07) 869-876
• 7 Aapro M, Gralla RJ, Herrstedt J, Molassiotis A, Roila F. MASCC/ESMO antiemetic guideline 2016: with updates in 2019. Switzerland: European Society for Medical Oncology (ESMO);; 2016
• 8 Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R. et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 2003; May; 39 (08) 1074-1080
• 9 National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines). NCCN 2011; 2: 19-21
• 10 Patel P, Robinson PD, Thackray J, Flank J, Holdsworth MT, Gibson P. et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. Pediatr Blood Cancer. 2017 Oct;64(10)
• 11 Sing EPC, Robinson PD, Flank J, Holdsworth M, Thackray J, Freedman J. et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline. Pediatr Blood Cancer 2019; May; 66 (05) e27646
• 12 Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure A, Pastorelli D. et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 2012; Aug; 23 (08) 1986-1992
• 13 Abunahlah N, Sancar M, Dane F, Özyavuz MK. Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life. Int J Clin Pharm 2016; Dec; 38 (06) 1464-1476
• 14 Caracuel F, Muñoz N, Baños U, Ramirez G. Adherence to antiemetic guidelines and control of chemotherapy-induced nausea and vomiting (CINV) in a large hospital. J Oncol Pharm Pract 2015; Jun; 21 (03) 163-169
• 15 Laurentiis M, Bonfadini C, Lorusso V, Cilenti G, Di Rella F, Altavilla G. et al. Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study. Support Care Cancer 2018; Dec; 26 (12) 4021-4029
• 16 Gilmore JW, Peacock NW, Gu A, Szabo S, Rammage M, Sharpe J. et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract 2014; Jan; 10 (01) 68-74
• 17 Dupuis LL, Tomlinson GA, Pong A, Sung L, Bickham K. Factors associated with chemotherapy-induced vomiting control in pediatric patients receiving moderately or highly emetogenic chemotherapy: a pooled analysis. J Clin Oncol 2020; Aug; 38 (22) 2499-2509
• 18 Cohen L, Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007; May; 15 (05) 497-503
• 19 Mora J, Valero M, Di Cristina C, Jin M, Chain A, Bickham K. Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients. Pediatr Blood Cancer 2019; Jun; 66 (06) e27690
• 20 Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer 2011; Jan; 19 (01) 131-140
• 21 Sommariva S, Pongiglione B, Tarricone R. Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit Rev Oncol Hematol 2016; Mar; 99: 13-36
• 22 Holdsworth MT, Raisch DW, Frost J. Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer 2006; Feb; 106 (04) 931-940
• 23 Kishimoto K, Kawasaki K, Saito A, Kozaki A, Ishida T, Hasegawa D. et al. Prevention of chemotherapy-induced vomiting in children receiving multiple-day cisplatin chemotherapy: a hospital-based, retrospective cohort study. Pediatr Blood Cancer 2017; Feb; 64 (09) e26485
• 24 Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 2003; 8 (02) 187-198
• 25 Radhakrishnan V, Joshi A, Ramamoorthy J, Rajaraman S, Ganesan P, Ganesan TS. et al. Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: a double-blind, placebo-controlled, phase III randomized trial. Pediatr Blood Cancer 2019; Mar; 66 (03) e27551
• 26 Willier S, Stanchi KMC, Von Have M, Binder V, Blaeschke F, Feucht J. et al. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study. BMC Cancer 2019; Nov; 19 (01) 1118
• 27 Rapoport B, Smit T. Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy. Expert Opin Drug Safety 2017; Jun; 16 (06) 697-710
• 28 Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 2012; Jun; 684 (1-3): 1-7
• 29 Luisi FAV, Petrilli AS, Tanaka C, Caran EMM. Contribution to the treatment of nausea and emesis induced by chemotherapy in children and adolescents with osteosarcoma. Sao Paulo Med J 2006; 124 (02) 61-65
• 30 Fernández-Ortega P, Caloto MT, Chirveches E, Marquilles R, San Francisco J, Quesada A. et al. Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life. Support Care Cancer 2012; Dec; 20 (12) 3141-3148